Background: The management of hyperleukocytosis currently involves intensive supportive care for preventing tumor lysis syndrome (TLS)-associated metabolic abnormalities as well as cytoreduction procedures to reduce the white blood cell (WBC) count. These procedures are often equipment-intensive and may not be practised in developing countries with limited resources. Hence, it is not clear what would be the most effective strategy to manage hyperleukocytosis and prevent TLS. Procedure: All children ≤12 years, diagnosed with acute lymphoblastic leukemia (ALL) and hyperleukocytosis (WBC count >100 × 109/l) were administered L-asparginase (L-asp, 6,000 U/m2, i.m.) along with standard supportive care consisting of hydration, oral allopurinol administration and alkalization. The complete blood counts and biochemical parameters were monitored for 72 h. After 48 h, if the WBC count was >100 × 109/l, a repeat dose of L-asp was administered. Results: Twenty-one children (9 boys and 12 girls) with hyperleukocytic ALL were treated with L-asp. The median age of the children was 5.3 years (range 2-11 years). The median initial WBC count was 249 × 109/l (range 151-476 × 109/l). Twenty children received only one dose of L-asp. The mean reduction in WBC count achieved by treatment was 15.7, 42.0, 61.0, 76.4, 85.5 and 90.8% at 12, 24, 36, 48, 60 and 72 h, respectively. None of the patients developed TLS. Conclusions: Chemical cytoreduction by administering L-asp is an effective means of managing hyperleukocytosis and preventing TLS.

Keywords:
Hyperleukocytosis, Hyperuricemia, Hyperkalemia, Hyperphosphatemia, Cytoreduction
1.
Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM: Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012;26:117-122.
2.
Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A, McCarthy LJ: Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000;39:1-18.
3.
Lowe EJ, Pui CH, Hancock ML, Geiger TL, Khan RB, Sandlund JT: Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer 2005;45:10-15.
4.
Firwana BM, Hasan R, Hasan N, Alahdab F, Alnahhas I, Hasan S, Varon J: Tumor lysis syndrome: a systematic review of case series and case reports. Postgrad Med 2012;124:92-101.
5.
Eguiguren JM, Schell MJ, Crist WM, Kunkel K, Rivera GK: Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis. Blood 1992;79:871-875.
6.
Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M: Leukocytoreduction for acute leukemia. Ther Apher 2002;6:15-23.
7.
Ozdemir MA, Karakukcu M, Patiroglu T, Torun YA, Kose M: Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia. Acta Haematol 2009;121:56-62.
8.
Haase R, Merkel N, Diwan O, Elsner K, Kramm CM: Leukapheresis and exchange transfusion in children with acute leukemia and hyperleukocytosis. A single center experience. Klin Padiatr 2009;221:374-378.
9.
Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R: Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004;11(suppl 1):S45-S55.
10.
Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR: Weekly polyethylene glycol conjugated L-asparginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood 2000;96:1709-1715.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.